Trial Profile
A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo) with the Same Dose Levels of Insulin Degludec (Tresiba) in Steady State After 8 Days Multiple Dosing Regimen in Patients with Diabetes Mellitus Type 1
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2018
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 11 Nov 2016 Results published in a Sanofi media release.
- 12 Oct 2016 Status changed from recruiting to completed.
- 15 Sep 2016 Results published in the Sanofi Media Release